- Home
- IDN vs GNLX Comparison
IDN vs GNLX Comparison
Compare IDN & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDN
- GNLX
- Stock Information
- Founded
- IDN 1994
- GNLX 2001
- Country
- IDN United States
- GNLX United States
- Employees
- IDN N/A
- GNLX N/A
- Industry
- IDN Computer Software: Prepackaged Software
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- IDN Technology
- GNLX Health Care
- Exchange
- IDN Nasdaq
- GNLX Nasdaq
- Market Cap
- IDN 120.5M
- GNLX 96.6M
- IPO Year
- IDN 1999
- GNLX 2023
- Fundamental
- Price
- IDN $5.38
- GNLX $2.83
- Analyst Decision
- IDN Strong Buy
- GNLX Strong Buy
- Analyst Count
- IDN 3
- GNLX 4
- Target Price
- IDN $5.83
- GNLX $17.75
- AVG Volume (30 Days)
- IDN 583.3K
- GNLX 146.5K
- Earning Date
- IDN 08-07-2025
- GNLX 08-13-2025
- Dividend Yield
- IDN N/A
- GNLX N/A
- EPS Growth
- IDN N/A
- GNLX N/A
- EPS
- IDN N/A
- GNLX N/A
- Revenue
- IDN $20,211,000.00
- GNLX N/A
- Revenue This Year
- IDN $9.35
- GNLX N/A
- Revenue Next Year
- IDN $13.05
- GNLX N/A
- P/E Ratio
- IDN N/A
- GNLX N/A
- Revenue Growth
- IDN 4.55
- GNLX N/A
- 52 Week Low
- IDN $1.92
- GNLX $1.60
- 52 Week High
- IDN $6.49
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- IDN 60.65
- GNLX 57.73
- Support Level
- IDN $5.08
- GNLX $2.85
- Resistance Level
- IDN $5.63
- GNLX $3.29
- Average True Range (ATR)
- IDN 0.45
- GNLX 0.22
- MACD
- IDN -0.11
- GNLX 0.06
- Stochastic Oscillator
- IDN 21.28
- GNLX 64.74
About IDN Intellicheck Inc.
Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company include solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.